Cost-effectiveness of novel multiple sclerosis drug
Research Project | 10.12.2018 - 31.12.2019
|
10.12.2018
- 31.12.2019
Funding
Cost-effectiveness of siponimod in multiple sclerosis treatment
Novartis Pharma Schweiz AG, 12.2018-03.2021 (28)
PI : Schwenkglenks, Matthias.CI : Szucs, Thomas.
Publications
Schur, Nadine et al. (2021) ‘Cost Effectiveness and Budget Impact of Siponimod Compared to Interferon Beta-1a in the Treatment of Adult Patients with Secondary Progressive Multiple Sclerosis with Active Disease in Switzerland’, PharmacoEconomics, 39(5), pp. 563–577. Available at: https://doi.org/10.1007/s40273-021-01023-8.
Schur, Nadine et al. (2021) ‘Cost Effectiveness and Budget Impact of Siponimod Compared to Interferon Beta-1a in the Treatment of Adult Patients with Secondary Progressive Multiple Sclerosis with Active Disease in Switzerland’, PharmacoEconomics, 39(5), pp. 563–577. Available at: https://doi.org/10.1007/s40273-021-01023-8.
Members (4)
Matthias Schwenkglenks
Principal Investigator
Thomas Szucs
Co-Investigator
Arjun Bhadhuri
Project Member
